maltol

Maltol (3-Hydroxy-2-methyl-4H-pyran-4-one): A Comprehensive Reference

1. Identity and Chemical Characterization

Names and Classification

Maltol is a naturally occurring organic compound with the systematic name 3-hydroxy-2-methyl-4H-pyran-4-one, recognized for its role as a flavor enhancer that imparts a characteristic caramel-like odor and taste. With the chemical formula C₆H₆O₃, it exists as a white crystalline powder that is soluble in hot water and chloroform, with a melting point of 161–162 °C and an estimated boiling point of 285 °C. The compound is a heterocyclic aroma chemical belonging to the pyranone class of molecules. It is classified under chemical group 12, defined as "maltol derivatives and ketodioxane derivatives."

Maltol is known by several synonyms and trade names. These include Larixinic acid, Palatone, and Veltol. Its close structural analog, ethyl maltol (3-hydroxy-2-ethyl-4H-pyran-4-one), is a synthetically produced derivative that is more potent as a flavor enhancer but shares many physical and chemical properties. Together, maltol and ethyl maltol are among the most commonly used synthetic flavoring agents in food after vanillin.

Natural Sources

In nature, maltol is present in several plant-derived materials, including the bark of young larch trees (Larix decidua), pine needles (Abies alba and other Pinaceae species), chicory roots, and wood tars. It also occurs in processed plant foods such as roasted malt barley, baked bread, cereals, and other thermally treated items like coffee and cocoa. Concentrations in these natural sources remain generally low, typically ranging from trace amounts to a few ppm in roasted barley and similar substrates under controlled roasting conditions.

Maltol was first isolated in 1861 from the bark of larch trees by British chemist John Stenhouse. It has also been isolated from the alkaline hydrolysis products of streptomycin. Maltol is also a significant non-saponin component generated by Maillard reactions during the processing of red ginseng (Panax ginseng): apparent changes happen to other secondary metabolites such as the increase in the contents of phenolic compounds and reducing sugars, and furthermore, the presence of some Maillard reaction products like maltol was also engaged during black ginseng processing.

The crude resin derived from fir trees normally contains 3 to 8% maltol, representing among the richer natural concentrations found in plant sources.

Common Forms and Preparations

Maltol is now manufactured synthetically through several industrial pathways, primarily derived from furfural derivatives, furfuryl alcohol, or pyruvic acid intermediates. Maltol can also be obtained in very small amounts from the destructive distillation products of wood, and by a partially synthetic process from kojic acid, which is obtained from fermentation media.

For food use, maltol is supplied as a purified crystalline white powder. Although its flavor enhancement effect is not as strong as that of ethyl maltol, it is less volatile and can be used at high temperatures, such as in baked and high-temperature-processed food. In pharmaceutical contexts, its most clinically significant preparation is ferric maltol, a stable iron complex. Ferric maltol is a new oral iron replacement therapy designed to optimize iron absorption while reducing the gastrointestinal adverse events associated with unabsorbed free iron. Ferric maltol is marketed under the brand name Accrufer (US) / Feraccru (EU). ACCRUFER (ferric maltol) capsules are for oral use; initial U.S. approval was 2019.

2. Traditional and Historical Use

Discovery in Botanical Materials

The history of maltol as a recognized chemical entity begins in 19th-century Europe. First isolated in 1861 from the bark of larch trees by British chemist John Stenhouse, maltol was subsequently found in roasted malt, chicory, bread, milk, cocoa, coffee, and nuts, where it forms through Maillard reactions and caramelization during heating processes. In particular, its isolation from coniferous trees such as larch trees (Larix decidua Mill), pine trees, and pine needles (Abies alba Mill., Pinaceae) has been reported since the turn of the century.

Maltol in Red Ginseng Traditions

While maltol itself was not identified by this name in traditional medicine, it is an active constituent generated during the preparation of red ginseng and black ginseng — preparations with well-documented histories of use in East Asian medicine. Panax ginseng has been used as a superior herb in traditional Chinese medicine (TCM) for at least 2,000 years. With its outstanding effects of nourishing, tranquilizing, and benefiting the mind, it has been traditionally used as an herbal remedy for a variety of ailments, such as physical weakness, thirst, or insomnia with palpitations. It has been reported that Korean Red Ginseng has been manufactured for 1,123 years as described in the GoRyeoDoGyeong record. In oriental medicine, red ginseng is slightly warm in nature, sweet and slightly bitter in taste, and has been used as a representative herbal medicine that is effective in promoting health and preventing diseases, such as in replenishing energy and making the body fluid by entering the spleen, lungs, and heart.

The relevance of maltol to these traditions is that it arises during the traditional processing step: red ginseng is prepared by selecting 4–6 year-old Panax ginseng C.A. Meyer, a perennial herb belonging to the family Araliaceae, and then steaming and drying the same in an unpeeled state. Maltol is a food-flavoring agent and Maillard reaction product formed during the processing of red ginseng (Panax ginseng, C.A. Meyer) and has been confirmed to exert a hepatoprotective effect in alcohol-induced oxidative damage in mice. In modern research, maltol isolated from Korean red ginseng (KRG) has served as the subject of numerous pharmacological studies, representing a direct scientific elaboration of the traditional attribution of therapeutic properties to these processed ginseng preparations.

Early Commercial and Food Use

Early commercial production of maltol was from the destructive distillation of wood. Its use as a food-flavoring agent has been established for many decades, predating modern clinical interest in its pharmacological properties. Because of its caramel-butterscotch odor, and suggestive of fruity-strawberry aroma in dilute solutions, maltol is used as a food additive mainly in confectionery and bakery products.

3. Key Constituents and Mechanisms of Action

Structural Features and Core Chemistry

The pyrones, 3-hydroxy-2-methyl-4-pyrone (maltol) and 3-hydroxy-2-ethyl-4-pyrone (ethyl maltol), chelate iron with a high affinity and selectivity. This chelation capacity is central to multiple mechanisms of action attributed to maltol. The resulting 1:3 (metal–ligand) complexes, being neutral, are able to partition readily across cell membranes and thus may facilitate iron transport across the intestinal wall. In biological applications, maltol is an excellent spectator ligand; it forms stable neutral metal complexes with the following properties: (a) water solubility, (b) reasonable hydrolytic stability, and (c) significant lipophilicity.

Antioxidant Mechanisms

Maltol has antioxidant and anti-inflammatory activities. Its antioxidant actions have been characterized in multiple model systems. In hepatic studies, the levels of hepatic antioxidants such as catalase (CAT), superoxide dismutase (SOD), and glutathione peroxidase (GSH-Px) were elevated by maltol pretreatment, compared to the alcohol group. In mouse models, maltol dramatically attenuated the reduction of hepatic CAT, GSH, and SOD levels, and the over-expression of CYP2E1 and HO-1, as evaluated by immunofluorescence staining.

Anti-Inflammatory Mechanisms: NLRP3 Inflammasome Inhibition

A specific, well-characterized molecular mechanism of maltol is its inhibition of inflammasome activation. The inflammasome causes the maturation and secretion of interleukin (IL)-1β and IL-18 through the activation of caspase-1 (Casp1), which contributes to various inflammatory diseases. LPS-primed macrophages were treated with a trigger of NLRP3, NLRC4, AIM2, or non-canonical inflammasomes in the presence of maltol. Maltol inhibited the activation of NLRP3 and non-canonical inflammasomes, but it did not alter the other inflammasomes. Maltol attenuated the activity of Casp1 similarly to Z-VAD-FMK, a pan-caspase inhibitor, but did not change Casp4 activity. Hence, maltol interrupts NLRP3 signaling by inhibiting ROS production and Casp1 activity.

Anti-Apoptotic Mechanisms

The findings from cisplatin studies suggest that maltol may act as an anti-apoptosis agent through restoring the expression of Bcl-2 and inhibiting pro-caspase 3, 8, 9 cleavages. Additionally, maltol restored the reduction of PI3K/Akt and mTOR levels by cisplatin through increasing AMPK expression in cisplatin-treated HEK293 cells. Maltol also suppressed the expression of Bax and caspase 3 by inhibiting the p53 activity in HEK293 cells.

NF-κB and PI3K/Akt Signaling

Investigation of the protective effect and mechanisms of action of maltol on APAP-induced liver injury in vivo demonstrates that maltol exerts a significant liver protection effect, which may partly be ascribed to its anti-inflammatory and anti-apoptotic action via regulation of the PI3K/Akt signaling pathway. In retinal ganglion cell studies, the active form of phosphorylated NF-κB (pNF-κB) increased under oxidative stress, but maltol treatment reduced it to an unstressful level. The data revealed that maltol attenuated the oxidative stress-induced injury in primary mouse retinal ganglion cells (RGCs), and its neuroprotective and neurite outgrowth effects seemed to be related to NF-κB signaling.

Metal Chelation: Iron, Aluminum, and Vanadium Complexes

Maltol chelates metal ions such as Fe³⁺ and Al³⁺, and is reported to increase uptake of aluminum and iron in the body. Maltol, deferasirox, and 8-hydroxyquinoline are lipophilic chelators that form lipophilic metal complexes and can cause an increase in iron and other metal absorption. A parallel metabolic pathway has been identified: a parallel pathway of iron absorption may involve lipophilic dietary chelating molecules like maltol.

In the context of vanadium chemistry, 3-hydroxy-2-methyl-4-pyrone and 2-ethyl-3-hydroxy-4-pyrone (maltol and ethyl maltol, respectively) have proven especially suitable as ligands for vanadyl ions, in potential insulin-enhancing agents for diabetes mellitus. The most potent vanadium form is obtained by combining vanadium in a 1:2 ratio with maltol, resulting in a water-soluble and neutral vanadium metal complex, [VO(MA)₂], where MA = maltol; also known as bis(maltolato)oxovanadium(IV) (BMOV), a proven insulin-enhancing agent.

Aryl Hydrocarbon Receptor (AhR) Pathway

A potentially dual-edged mechanism involves cytochrome P450 induction: maltol has been shown to induce the cytochrome P450 1a1 (Cyp1a1) enzyme in hepatic cell models. Treatment of Hepa 1c1c7 cells with maltol significantly induced Cyp1a1 at mRNA, protein, and activity levels in a concentration-dependent manner. In addition, maltol induced aryl hydrocarbon receptor (AhR)-dependent luciferase reporter gene expression, suggesting an AhR-dependent mechanism. This was the first demonstration that the food flavoring agent maltol can directly induce Cyp1a1 gene expression in an AhR-dependent manner and represents a novel mechanism by which maltol may promote carcinogenicity and toxicity — a finding that warrants careful consideration in the context of chronic or high-dose use (discussed further in the Safety section).

4. Scientific Evidence by Area of Use

4.1 Iron Deficiency Anemia (Ferric Maltol): Human Clinical Evidence — Strong

The most robustly evidenced therapeutic application of maltol is in its ferric iron complex form. Ferric maltol is a novel oral iron therapy based on a stable complex of ferric (Fe³⁺) iron with maltol (3-hydroxy-2-methyl-4H-pyran-4-one). Ferric maltol, developed by Shield Therapeutics, is a novel, stable, and non-salt oral iron supplement. It was approved by the FDA for the treatment of adults with low iron stores.

The pivotal clinical program comprised three randomized, placebo-controlled Phase 3 trials. This phase-3 clinical trial program comprised two identical clinical trials that evaluated patients with UC and CD according to a 12-week, randomized, double-blind, placebo-controlled, multicenter study design. Data from both trials were prospectively collected and analyzed as a single dataset based on a predefined statistical analysis plan. The program was conducted across centers in Austria, Germany, Hungary, and the United Kingdom between August 2011 and December 2013.

Trials ST10-01-301 and ST10-01-302 enrolled patients with IBD who had failed other oral iron replacement products or otherwise could not tolerate oral iron preparations due to adverse effects. They enrolled 128 patients (age range 18–76 years, 45 males and 83 females) with quiescent IBD and baseline hemoglobin concentrations between 9.5 g/dL and 12–13 g/dL and ferritin <30 g/dL. Significant improvements in Hb were observed with ferric maltol versus placebo at weeks 4, 8, and 12: mean (SE) 1.04 (0.11) g/dL, 1.76 (0.15) g/dL, and 2.25 (0.19) g/dL, respectively (P < 0.0001 at all time-points). Hb was normalized in two-thirds of patients by week 12. The safety profile of ferric maltol was comparable with placebo, with no impact on inflammatory bowel disease severity.

A third pivotal study (ST10-01-303) extended the evidence to chronic kidney disease (CKD): study ST10-01-303 enrolled patients with non-dialysis-dependent chronic kidney disease (CKD) and iron deficiency anemia. In patients with both iron deficiency anemia and quiescent IBD and in patients with both iron deficiency anemia and CKD, treatment with ferric maltol 30 mg orally twice daily for 12 or 16 weeks, respectively, resulted in statistically significant increases in Hb compared to placebo (p < 0.05).

The cumulative evidence is substantial: ferric maltol has been studied in clinical trials involving almost 750 adults and adolescents with iron-deficiency anemia associated with IBD, CKD, and other underlying conditions, and it has been widely used in clinical practice. Published evidence for ferric maltol demonstrates consistent and clinically meaningful improvements in hemoglobin and measures of iron availability (ferritin and transferrin saturation) and shows that it is well-tolerated over long-term treatment for up to 64 weeks — an important consideration in patients with chronic underlying conditions such as IBD and CKD.

Evidence strength: Strong. Multiple Phase 3 RCTs with statistically significant and clinically meaningful primary endpoints, regulatory approval in both the US and EU.

4.2 Hepatoprotection: Preclinical Evidence — Promising but No Human Data

The efficacy of maltol on liver inflammation and fibrosis has been reported. Multiple distinct hepatotoxicity models in rodents have been studied.

Alcohol-induced liver injury: Maltol used in one study was isolated from red ginseng (Panax ginseng C.A. Meyer) and analyzed by HPLC and mass spectrometry. Pretreatment with maltol (12.5, 25 and 50 mg/kg; 15 days) drastically prevented the elevated activities of AST, ALT, ALP, and TG in serum and the levels of MDA, TNF-α, and IL-1β in liver tissue (p < 0.05). This investigation was the first report indicating that pretreatment of maltol is effective in the prevention of alcohol-induced hepatic damage in mice. It is speculated that the mechanism of hepatoprotection may be due to the alleviation of oxidative stress via preventing lipid peroxidation and ameliorating hepatic antioxidant status.

CCl₄-induced liver injury: In the mouse model of CCl₄-induced liver injury, inflammatory responses were inhibited, serum levels of ALT and AST were reduced, cell apoptosis was suppressed, and liver injury was alleviated by maltol, demonstrating that maltol may be an efficient hepatoprotective agent.

APAP (acetaminophen)-induced hepatotoxicity: Results indicated that maltol pretreatment exerted an important potential and beneficial effect on APAP-triggered acute liver injury and found that its molecular mechanisms of action were related to the alteration of oxidative stress-mediated inflammation and apoptosis, partly via regulation of the PI3K/Akt pathway. In this study, maltol was administered orally at 50 and 100 mg/kg daily for seven consecutive days, then a single intraperitoneal injection of APAP (250 mg/kg) was performed.

Liver fibrosis: Maltol mitigated thioacetamide-induced liver fibrosis and inhibited thioacetamide-induced ALT, AST, and oxidative stress indices.

Evidence strength: Preliminary — animal/in vitro only. All hepatoprotective studies identified are conducted in rodent models. No published human clinical trials on maltol as a standalone hepatoprotective agent were identified. Results should not be extrapolated to clinical practice without further study.

4.3 Neuroprotection: Preclinical Evidence — Preliminary

Maltol was reported to have a neuroprotective effect on retinal ganglion cells under oxidative stress. In mouse retinal ganglion cell studies, cell viability was recovered with maltol as measured by ATP assay. The oxidative stress significantly increased the number of TUNEL-positive RGCs, but maltol drastically reduced the proportion of those apoptotic cells. The oxidative stress hampered the neurite outgrowth of the RGCs, whereas maltol restored their ability to sprout neurites. Maltol has potential as a new neuroprotective therapeutic agent for oxidative stress-related ocular diseases.

The neuroprotective effect of maltol on oxidative stress in the brain of mice was also investigated. Additionally, maltol may serve as a valuable potential drug to prevent cisplatin-induced nephrotoxicity, and the underlying molecular mechanisms of maltol action may involve intracellular AMPK/PI3K/Akt and p53 signaling pathways.

Evidence strength: Preliminary — in vitro and animal models only. No human clinical studies were identified for maltol as a standalone neuroprotective agent.

4.4 Vanadium Complex (BMOV) for Diabetes: Early Clinical Evidence — Incomplete

Maltol and ethyl maltol have proven especially suitable as ligands for vanadyl ions in potential insulin-enhancing agents for diabetes mellitus. Both bis(maltolato)oxovanadium(IV) (BMOV), and the ethylmaltol analog, bis(ethylmaltolato)oxovanadium(IV) (BEOV), have the desired intermediate stability for pro-drug use and have undergone extensive pre-clinical testing for safety and efficacy. Pharmacokinetic evaluation indicates a pattern of biodistribution consistent with fairly rapid dissociation and uptake, binding to serum transferrin for systemic circulation and transport to tissues, with preferential uptake in bone.

Most promising in the field of potential applications of vanadium-based medications is the antidiabetic effect of simple coordination compounds such as VO(maltol)₂, a complex that has been checked in clinical tests phase I and II. These bis-ligand oxovanadium(IV) (VOL₂) compounds have a clear advantage over inorganic vanadyl sulfate in terms of bioavailability and pharmaceutical efficacy.

Evidence strength: Early-phase human data (Phase I/II only). The maltol-vanadium complex BMOV has been tested in early-phase clinical trials, but there are no published Phase 3 human trials, and no regulatory approval has been granted for this application. Evidence is insufficient to support clinical recommendations.

4.5 Anti-Inflammatory Activity: Preclinical Evidence — Mechanistically Interesting

One study specifically examined the effects of maltol on inflammasome activation in macrophages and mice. LPS-primed macrophages were treated with a trigger of NLRP3, NLRC4, AIM2, or non-canonical inflammasomes in the presence of maltol. The secretion of IL-1β and IL-18 and the cleavage of Casp1 were analyzed as indices of inflammasome activation. Maltol also attenuated IL-1β secretion resulting from the inflammasome activation in mice.

Evidence strength: Preliminary — in vitro and mouse models. No human clinical trials were identified specifically targeting maltol's anti-inflammatory properties as a standalone intervention.

4.6 Cosmetic Use — Skin Lightening and Antioxidant: Limited Evidence

Maltol has been proven to be an in-vivo skin lightener, and with an ex-vivo melanogenesis-reducing activity, together with antioxidant activity, skin tone, and skin quality improving activities. In example assays, maltol can effectively reduce melanogenesis activity with an IC50 of 0.065 g/L in B16 cultured melanocyte assays. As regards its melanogenesis inhibiting activities, maltol is a tyrosinase inhibitor and also an antioxidant, including scavenging the singlet oxygen generated by the action of sunlight on skin. Maltol is used widely as a food and cosmetic supplement.

Evidence strength: Limited — primarily in vitro and cosmetic patent-level data. Robust peer-reviewed human clinical trials specifically assessing maltol for skin lightening were not identified in the literature reviewed.

5. Body Systems and Health Areas Associated with Maltol

• Hematopoietic/Iron Metabolism System: The maltol iron complex is used for increasing iron absorption. Ferric maltol is an approved iron replacement product for iron deficiency and iron deficiency anemia.
• Hepatic System: The efficacy of maltol on liver inflammation and fibrosis has been reported across multiple preclinical models including alcohol-, CCl₄-, APAP-, and thioacetamide-induced injury.
• Nervous System: Preclinical studies report neuroprotective effects on retinal ganglion cells under oxidative stress, seemingly related to NF-κB signaling.
• Metabolic/Endocrine System: BMOV, the most potent vanadium form, is obtained by combining vanadium in a 1:2 ratio with maltol, resulting in a water-soluble and neutral vanadium metal complex known as a proven insulin-enhancing agent.
• Immune/Inflammatory System: Maltol inhibits NLRP3 and non-canonical inflammasome activation, reducing IL-1β and IL-18 production in macrophages and in animal models of acute inflammation.
• Integumentary System (Skin): Maltol functions as a tyrosinase inhibitor and antioxidant in cosmetic applications, with in vitro and ex vivo evidence for melanogenesis reduction.
• Renal System: Administration of maltol or related compounds may be considered as a therapeutic strategy to prevent cisplatin-induced acute renal injury — based on preclinical data only.

6. Dosage Forms and Reported Dosages

Food Use

Concentrations of maltol in natural food sources remain generally low, typically ranging from trace amounts to a few ppm in roasted barley and similar substrates. As a food additive (flavor enhancer), maltol is used in very small quantities; the EFSA FEEDAP Panel concludes that maltol added to the feed of all animal species is safe at the normal use level of 5 mg/kg feed.

Ferric Maltol (Pharmaceutical — Approved)

The ferric maltol product sought approval for the treatment of iron deficiency in adults. The proposed dosing regimen is 30 mg by mouth (PO) twice daily (BID), taken one hour before or two hours after a meal. The approved adult dose of 30 mg twice daily was established through Phase 3 studies demonstrating efficacy and safety in adults with iron deficiency anemia associated with IBD and CKD. ACCRUFER is indicated for the treatment of iron deficiency in adult and pediatric patients 10 years of age and older.

Higher doses have also been explored: the inventors found that, despite contradictory teachings in prior art that doses above 30 mg per day would not be beneficial, dosages of up to 90 mg twice daily result in increased iron absorption and hemoglobin production, appear well-tolerated, and are safe.

Preclinical Dosages Reported in Research Studies

These dosages are reported as used in animal research and are not human therapeutic recommendations:

• Hepatoprotective studies (alcohol-induced liver injury, mice): Pretreatment with maltol at 12.5, 25, and 50 mg/kg for 15 days was used.
• APAP-induced hepatotoxicity (mice): Maltol was administered orally at 50 and 100 mg/kg daily for seven consecutive days.

7. Safety Considerations and Interactions

Regulatory Safety Status

Maltol is considered safe by the FDA according to existing data and granted GRAS (Generally Recognized as Safe) status. It is authorized for use as a flavoring agent (FL-no: 07.014) in the EU according to Annex I to Regulation (EU) No 1334/2008. EFSA concluded that the concern for genotoxicity in food could be ruled out in 2015. An acceptable daily intake (ADI) of "0–1 mg/kg bw" was set in 1981, but was withdrawn by JECFA in 2018.

Metal Chelation and Increased Absorption of Metals

The lipophilic chelation properties of maltol represent a key safety consideration. In contrast to hydrophilic chelators, lipophilic chelators such as maltol could increase the absorption of iron and other metals. Maltol chelates metal ions such as Fe³⁺ and Al³⁺, and is reported to increase uptake of aluminum and iron in the body. The potential for increased aluminum absorption is particularly notable because aluminum accumulation has been associated with neurotoxicity. This distinguishes maltol from chelators used for metal removal, such as deferoxamine and deferiprone, which are hydrophilic and function primarily by increasing iron excretion.

However, with respect to iron specifically, experimental evidence suggests that maltol-facilitated absorption is self-limiting at higher doses: enhanced ⁵⁹Fe uptake from maltol was evident at 0.7–70 micrograms but not at 700 micrograms, suggesting that use of these pyrones will not result in iron overload.

AhR-Mediated CYP1A1 Induction — Potential Toxicological Concern

Maltol induced aryl hydrocarbon receptor (AhR)-dependent luciferase reporter gene expression, suggesting an AhR-dependent mechanism. This was described as the first demonstration that the food flavoring agent maltol can directly induce Cyp1a1 gene expression in an AhR-dependent manner and represents a novel mechanism by which maltol promotes carcinogenicity and toxicity — an in vitro finding requiring further characterization and contextualization in terms of exposure levels relevant to human food consumption or supplementation.

Drug Interactions of Ferric Maltol

The iron in ferric maltol participates in a range of drug interactions mediated by divalent cation binding. Ferric maltol will decrease the level or effect of bictegravir (an antiretroviral) by cation binding in the GI tract; therapy modification and monitoring are advised. Ferric maltol may increase levels of calcium acetate by enhancing GI absorption; deferiprone decreases levels of ferric maltol by inhibition of GI absorption. Ferric maltol will decrease the level or effect of delafloxacin (a fluoroquinolone antibiotic) by cation binding in the GI tract. Sodium picosulfate/magnesium oxide/anhydrous citric acid decreases levels of ferric maltol by cation binding; this interaction requires separation of administration by at least 2 hours before and not less than 6 hours after to avoid magnesium chelation.

Gastrointestinal Tolerability

The safety evaluation showed that ferric maltol was tolerated with primarily gastrointestinal adverse events. The ferric maltol formulation was specifically designed to address GI tolerability problems common to ferrous iron salts: oral ferric iron chelated with maltol can be administered with improved tolerability, and the total dose exposure of unabsorbed iron within the gastrointestinal tract is significantly reduced. In addition, the iron is retained in its chelated form if not absorbed, and this may reduce the risk of irritation within the gastrointestinal tract that is often seen with oral ferrous preparations.

Independent Absorption of Maltol and Iron from Ferric Maltol

An important pharmacokinetic feature distinguishing ferric maltol from concern about systemic maltol accumulation is that pharmacokinetic data from pivotal GCP studies conducted in both IBD patients and patients with IDA of any cause demonstrated that uptake of maltol and iron into the plasma after administration of ferric maltol displayed completely independent absorption profiles. This means that the intact iron-maltol complex dissociates before or during mucosal uptake, and systemic maltol exposure from therapeutic ferric maltol doses is not equivalent to systemic maltol accumulation.

Workplace and Physical Hazards

In the material safety data sheet for maltol, hazards for skin and eye contact and respiratory system are recognized. These are relevant primarily to occupational exposure in manufacturing or research contexts, not to food additive or pharmaceutical use at typical levels.

References

• PMC9598623 — Maltol, a Natural Flavor Enhancer, Inhibits NLRP3 and Non-Canonical Inflammasome Activation. Antioxidants 2022.
• PMC4303861 — Maltol, a Food Flavoring Agent, Attenuates Acute Alcohol-Induced Oxidative Damage in Mice. Nutrients 2015.
• PubMed 30142916 — The Liver Protection Effects of Maltol on Carbon Tetrachloride-Induced Acute Liver Injury in Mice. 2018.
• PMC6769439 — Maltol Improves APAP-Induced Hepatotoxicity by Inhibiting Oxidative Stress and Inflammation Response via NF-κB and PI3K/Akt Signal Pathways. Antioxidants 2019.
• Scientific Reports 2018 — The Protective Effects of Maltol on Cisplatin-Induced Nephrotoxicity through the AMPK-Mediated PI3K/Akt and p53 Signaling Pathways.
• Inflammatory Bowel Diseases 2015 — Ferric Maltol Is Effective in Correcting Iron Deficiency Anemia in Patients with IBD: Results from a Phase-3 Clinical Trial Program.
• PubMed 25545376 — Ferric maltol is effective in correcting iron deficiency anemia in patients with IBD: results from a phase-3 clinical trial program.
• PMC8509126 — Iron Replacement Therapy with Oral Ferric Maltol: Review of the Evidence and Expert Opinion.
• FDA NDA 212320 — Multi-Disciplinary Review and Evaluation: Ferric Maltol (Accrufer). 2019.
• PMC8197347 — New Era in the Treatment of Iron Deficiency Anaemia Using Trimaltol Iron and Other Lipophilic Iron Chelator Complexes. Molecules 2021.
• PubMed 19162329 — Vanadium treatment of type 2 diabetes: a view to the future. Journal of Inorganic Biochemistry 2009.
• ScienceDirect 2023 — A comprehensive review of anti-diabetic activity of vanadium-based complexes via PTP-1B inhibition mechanism.
• PubMed 2883285 — Effects of the pyrones, maltol and ethyl maltol, on iron absorption from the rat small intestine.
• PubMed 26893541 — New developments and controversies in iron metabolism and iron chelation therapy.
• PMC7177276 — Advances on Chelation and Chelator Metal Complexes in Medicine. International Journal of Molecular Sciences 2020.
• EFSA Journal 2016 — Safety and efficacy of maltol belonging to chemical group 12 when used as flavouring for all animal species.
• NCATS Inxight Drugs — MALTOL (National Center for Advancing Translational Sciences).
• PubMed 26869832 — Characterization of Korean Red Ginseng (Panax ginseng Meyer): History, preparation method, and chemical composition.
• ScienceDirect 2015 — Characterization of Korean Red Ginseng: History, preparation method, and chemical composition.
• PMC8584792 — Alzheimer's Disease and Diabetes Mellitus in Comparison: The Therapeutic Efficacy of the Vanadium Compound. International Journal of Molecular Sciences 2021.
• Medscape Drug Reference — Accrufer (ferric maltol): Dosing, Indications, Interactions, Adverse Effects.
• FoodAdditives.net — What is Maltol in food: Natural sources, Uses and Safety.